US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 – MedPro

US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 – MedPro

0

  • Year: 2017
  • Scope: 2013-2023
  • Region: United States
  • Published Date: 11/1/16
  • Pages: 40
  • Type: MedPro

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.

Segments Covered in this Diabetes Monitoring, Treatment and Drug Delivery Procedure Volume Research

This market study focuses specifically on the volume of procedures in the diabetes monitoring, treatment and drug delivery market. It includes analysis of procedures in the following segments:

  • Professional CGM Sensors Placed

 

This data is then displayed over the forecast period, 2013-2023, outlining the exact growth rates for procedures in these segments. If you’re interested in seeing the trends in procedures to formulate your market sizing and forecasts this is the most accurate and most affordable way to do it.

About Procedure Volume Research (MedPro)

Our analysts meticulously research for 3 to 4 months to put together a suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedPro is one portion of that analysis that outlines only the procedure volumes and forecasts for each market in that suite of reports.

This procedural analysis is incorporated in our market size analysis and forecasting which are available when purchasing a MedSuite, MedView or MedCore. For a deeper description on these product types click here or contact us to have a product consultant help you find the data you need.

Where Do We Get Diabetes Monitoring, Treatment and Drug Delivery Procedure Data?

Our team of analysts has proprietary data that we’ve been collecting for over a decade as well as government and private databases like that from CMS and hospital records. By looking at multiple sources we are able to triangulate on diabetes monitoring, treatment and drug delivery procedure volumes that influence and coincide with our overall market sizing.

Trends Affecting the Diabetes Monitoring, Treatment and Drug Delivery Market

Continuous glucose monitoring (CGM) represented the fastest growing segment in the total U.S. diabetes monitoring, treatment and drug delivery market in 2016. Growth of the segment can be attributed to the expanding installed base of CGM users, which experienced particularly high growth in 2015 and 2016. A recent vote by the Clinical Chemistry and Clinical Toxicology Devices panel of the FDA favored a non-adjunctive label that would allow DexCom’s G5® Mobile users to make insulin dosing decisions based on CGM data, as opposed to traditional blood glucose meter data.

Questions This Report will Help You Answer

  • What is affecting the volume of procedures in the U.S.?
  • How many procedures were done in 2016?
  • How many procedures were done historically?
  • How many procedures can we expect in 2023 and what is the growth trend?


The "US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedSuite" includes analysis on the following companies currently active in this market:
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Thank you!

CLOSE
Report Type Info

Single License: A single license is for use by a single individual only. Usage rights may not be transferred, sold or distributed by any means.

Site License: A site license allows sharing of the reports between various users within the purchasing company’s designated business address within this agreement.

Corporate License: A corporate license is for the use of one corporation. A corporation is defined as any business entity incorporated under a single name. Separate corporations operating under the same parent company are not included in this license.

Executive Summary: An in-depth summary of the reports associated with the related MedSuite product.

CLOSE

Login

Sign Up

Already have an account? Sign in

×